Annovis Bio (ANVS) Stock Forecast, Price Target & Predictions
ANVS Stock Forecast
Annovis Bio stock forecast is as follows: an average price target of $23.50 (represents a 193.38% upside from ANVS’s last price of $8.01) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ANVS Price Target
The average price target for Annovis Bio (ANVS) is $23.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $21.00. This represents a potential 193.38% upside from ANVS's last price of $8.01.
ANVS Analyst Ratings
According to 4 Wall Street analysts, Annovis Bio's rating consensus is 'Buy'. The analyst rating breakdown for ANVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Annovis Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Jason Kolbert | EF Hutton | $21.00 | $7.87 | 166.84% | 162.17% |
| Apr 30, 2024 | Sumant Kulkarni | Canaccord Genuity | $26.00 | $7.28 | 257.14% | 224.59% |
The latest Annovis Bio stock forecast, released on Aug 13, 2024 by Jason Kolbert from EF Hutton, set a price target of $21.00, which represents a 166.84% increase from the stock price at the time of the forecast ($7.87), and a 162.17% increase from ANVS last price ($8.01).
Annovis Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $21.00 | $23.50 |
| Last Closing Price | $8.01 | $8.01 | $8.01 |
| Upside/Downside | -100.00% | 162.17% | 193.38% |
In the current month, the average price target of Annovis Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Annovis Bio's last price of $8.01. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Aug 13, 2024 | EF Hutton | - | Buy | Initialise |
| Jul 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 02, 2024 | Rodman & Renshaw | Buy | Buy | Hold |
| Jun 04, 2024 | Rodman & Renshaw | - | Buy | Initialise |
Annovis Bio's last stock rating was published by Canaccord Genuity on Sep 03, 2024. The company gave ANVS a "Buy" rating, the same as its previous rate.
Annovis Bio Financial Forecast
Annovis Bio Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Mar 27 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $12.12M | $11.44M | $11.21M | $10.98M | - | - | - | - | - | - | - | - | - |
| High Forecast | $12.12M | $11.44M | $11.21M | $10.98M | - | - | - | - | - | - | - | - | - |
| Low Forecast | $12.12M | $11.44M | $11.21M | $10.98M | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annovis Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Annovis Bio EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Mar 27 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict ANVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annovis Bio's previous annual EBITDA (undefined) of $NaN.
Annovis Bio Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Mar 27 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-8.05M | $-8.05M | $-7.58M | $-6.33M | $-5.54M | $-4.86M | $-4.47M | $-5.81M | $-7.10M |
| High Forecast | - | - | - | - | $-8.05M | $-8.05M | $-7.58M | $-6.33M | $-5.54M | $-4.86M | $-4.47M | $-3.45M | $-7.10M |
| Low Forecast | - | - | - | - | $-8.05M | $-8.05M | $-7.58M | $-6.33M | $-5.54M | $-4.86M | $-4.47M | $-8.08M | $-7.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annovis Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Annovis Bio SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Mar 27 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annovis Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANVS last annual SG&A of $NaN (undefined).
Annovis Bio EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Mar 27 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-0.71 | $-0.71 | $-0.67 | $-0.56 | $-0.49 | $-0.43 | $-0.40 | $-0.51 | $-0.63 |
| High Forecast | - | - | - | - | $-0.71 | $-0.71 | $-0.67 | $-0.56 | $-0.49 | $-0.43 | $-0.40 | $-0.31 | $-0.63 |
| Low Forecast | - | - | - | - | $-0.71 | $-0.71 | $-0.67 | $-0.56 | $-0.49 | $-0.43 | $-0.40 | $-0.71 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Annovis Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANVS previous annual EPS of $NaN (undefined).
Annovis Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.20 | $10.00 | 733.33% | Buy |
| NVAX | Novavax | $13.61 | $74.67 | 448.64% | Buy |
| ANVS | Annovis Bio | $8.01 | $23.50 | 193.38% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| AVXL | Anavex Life Sciences | $5.31 | $11.00 | 107.16% | Buy |
| IMNM | Immunome | $15.97 | $30.33 | 89.92% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AXSM | Axsome Therapeutics | $93.67 | $117.83 | 25.79% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ANVS Forecast FAQ
Is Annovis Bio a good buy?
Yes, according to 4 Wall Street analysts, Annovis Bio (ANVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of ANVS's total ratings.
What is ANVS's price target?
Annovis Bio (ANVS) average price target is $23.5 with a range of $21 to $26, implying a 193.38% from its last price of $8.01. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Annovis Bio stock go up soon?
According to Wall Street analysts' prediction for ANVS stock, the company can go up by 193.38% (from the last price of $8.01 to the average price target of $23.5), up by 224.59% based on the highest stock price target, and up by 162.17% based on the lowest stock price target.
Can Annovis Bio stock reach $12?
ANVS's average twelve months analyst stock price target of $23.5 supports the claim that Annovis Bio can reach $12 in the near future.
What are Annovis Bio's analysts' financial forecasts?
Annovis Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.312M (high $-24.312M, low $-24.312M), average SG&A $0 (high $0, low $0), and average EPS is $-2.15 (high $-2.15, low $-2.15). ANVS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $45.74M (high $45.74M, low $45.74M), average EBITDA is $0 (high $0, low $0), average net income is $0 (high $0, low $0), average SG&A $0 (high $0, low $0), and average EPS is $0 (high $0, low $0).